• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4: Sc Capital 1 Llc disposed of 1,091,894 shares, closing all direct ownership in the company

    12/6/22 8:52:33 PM ET
    $ACON
    Medical Specialities
    Health Care
    Get the next $ACON alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
    X
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person*
    SC Capital 1 LLC

    (Last) (First) (Middle)
    ONE COMPOUND DRIVE

    (Street)
    HUTCHINSON KS 67502

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Aclarion, Inc. [ ACON ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    Officer (give title below) X Other (specify below)
    Former 10% Owner
    3. Date of Earliest Transaction (Month/Day/Year)
    12/02/2022
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    Form filed by One Reporting Person
    X Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 12/02/2022 J(1) 1,091,894(2) D(1) $0(1) 0 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    1. Name and Address of Reporting Person*
    SC Capital 1 LLC

    (Last) (First) (Middle)
    ONE COMPOUND DRIVE

    (Street)
    HUTCHINSON KS 67502

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    DIRKS MICHAEL W

    (Last) (First) (Middle)
    ONE COMPOUND DRIVE

    (Street)
    HUTCHINSON KS 67502

    (City) (State) (Zip)
    Explanation of Responses:
    1. On December 5, 2022, SC Capital 1 LLC ("SC Capital") effected a pro rata distribution of the Issuer's common stock held by SC Capital to each of the members of SC Capital.
    2. Michael W. Dirks serves as the manager for SC Capital and may be deemed to have voting and investment power over any shares held by SC Capital. Mr. Dirks disclaims beneficial ownership of any such shares except to the extent of his pecuniary interests therein, and this report shall not be deemed an admission that Mr. Dirks is the beneficial owner of any securities held by SC Capital for purposes of Section 16 or for any other purpose.
    /s/ Michael W. Dirks 12/06/2022
    /s/ Michael W. Dirks 12/06/2022
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ACON alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ACON

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ACON
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Thramann Jeffrey John

      4 - Aclarion, Inc. (0001635077) (Issuer)

      3/28/23 8:30:04 PM ET
      $ACON
      Medical Specialities
      Health Care
    • SEC Form 4: Thramann Jeffrey John bought $1,000 worth of Series A Preferred Stock (1 units at $1,000.00)

      4 - Aclarion, Inc. (0001635077) (Issuer)

      2/21/23 4:02:40 PM ET
      $ACON
      Medical Specialities
      Health Care
    • SEC Form 4: Ness Brent bought $9,769 worth of shares (18,500 units at $0.53), increasing direct ownership by 1,850% to 19,500 units

      4 - Aclarion, Inc. (0001635077) (Issuer)

      12/29/22 7:57:11 PM ET
      $ACON
      Medical Specialities
      Health Care

    $ACON
    SEC Filings

    See more
    • SEC Form 10-Q filed by Aclarion Inc.

      10-Q - Aclarion, Inc. (0001635077) (Filer)

      5/15/25 7:54:10 AM ET
      $ACON
      Medical Specialities
      Health Care
    • SEC Form DEF 14A filed by Aclarion Inc.

      DEF 14A - Aclarion, Inc. (0001635077) (Filer)

      5/12/25 8:27:41 PM ET
      $ACON
      Medical Specialities
      Health Care
    • SEC Form EFFECT filed by Aclarion Inc.

      EFFECT - Aclarion, Inc. (0001635077) (Filer)

      5/6/25 12:15:15 AM ET
      $ACON
      Medical Specialities
      Health Care

    $ACON
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Aclarion Inc.

      SC 13G/A - Aclarion, Inc. (0001635077) (Subject)

      11/13/24 3:06:29 PM ET
      $ACON
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by Aclarion Inc.

      SC 13G - Aclarion, Inc. (0001635077) (Subject)

      9/5/24 4:19:39 PM ET
      $ACON
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Aclarion Inc. (Amendment)

      SC 13G/A - Aclarion, Inc. (0001635077) (Subject)

      3/29/24 5:00:57 PM ET
      $ACON
      Medical Specialities
      Health Care

    $ACON
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Aclarion Announces Addition of Keck Medical Center of USC as CLARITY Trial Site

      USC Spine Center, part of Keck Medicine of USC, specializes in treating complex spine conditions with the latest cutting-edge technologiesCLARITY is a randomized clinical trial designed to demonstrate Nociscan's ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., May 20, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location

      5/20/25 6:00:00 AM ET
      $ACON
      Medical Specialities
      Health Care
    • Aclarion Announces Texas Back Institute as New CLARITY Trial Site

      Texas Back Institute is a world leader in advancing spine technology, science, and education, as well as patient careCLARITY is a randomized clinical trial designed to demonstrate Nociscan's ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., May 12, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back

      5/12/25 7:34:07 AM ET
      $ACON
      Medical Specialities
      Health Care
    • Aclarion Welcomes Advocate Health as CLARITY Trial Site

      Advocate Health actively participates in research studies and is an innovator in technology, including spine The CLARITY trial is designed to demonstrate Nociscan's ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., May 05, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the

      5/5/25 6:00:00 AM ET
      $ACON
      Medical Specialities
      Health Care

    $ACON
    Leadership Updates

    Live Leadership Updates

    See more
    • Aclarion Launches Second Clinical Utility and Economic (CLUE) Trial Site With First Surgeon in New Jersey

      CLUE is a Multi-center Trial to Identify how Often Nociscan's AI Data Changes the Initial Treatment Plan for Patients With Chronic Low Back Pain Dr. Justin Kubeck Will Initiate CLUE in New Jersey at Ocean Pain and Spine in Toms River BROOMFIELD, CO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW))), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today the expansion of the multi-center CLUE Trial to New Jersey. Justin Kubeck, MD, orthopedic spine surgeon and founder of Ocean Pain and Spine in Toms

      8/29/24 6:57:00 AM ET
      $ACON
      Medical Specialities
      Health Care
    • Aclarion Appoints Nicholas Theodore, MD as Principal Investigator for CLARITY Post-Market Trial Evaluating Nociscan in the Diagnosis and Treatment of Chronic Low Back Pain

      Nicholas Theodore, MD, FACS, FAANS, is Director of Neurosurgical Spine Center, Johns Hopkins, and Professor of Neurosurgery, Orthopaedics and Biomedical Engineering CLARITY is a Post-market, Multi-site Trial That Will Further Evaluate the Role of Nociscan in the Diagnosis and Surgical Ttreatment of Chronic Low Back Pain. CLARITY is Targeted to Begin in the Second Half of 2023. BROOMFIELD, CO, May 02, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW))), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pa

      5/2/23 7:00:00 AM ET
      $ACON
      Medical Specialities
      Health Care
    • Aclarion Appoints George Frey MD as Seventh Key Opinion Leader Surgeon Advisor

      Broomfield, CO, Jan. 17, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc. ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW))), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that George Frey MD, Founder of the Colorado Comprehensive Spine Institute, will advise the company as a key opinion leader (KOL). Dr. Frey is a renowned surgeon and inventor with dozens of US and worldwide patents in medical devices, technologies, and methods. Dr. Frey's experiences as a clinician and entrepreneur will provide valuable direction to Aclarion.

      1/17/23 8:29:31 AM ET
      $ACON
      Medical Specialities
      Health Care